Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + cisplatin versus gemcitabine + cisplatin as first-line treatment for advanced non-small cell lung cancer
ChiCTR-TRC-11001194Phase 2Completed
- Sponsor
- Naval Medical University
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemetrexed, cisplatin and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Naval Medical University. Primary endpoints: time to progression and progression-free survival. Started Mar 2008; status: completed.
02
Drugs
pemetrexedcisplatingemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001194.